Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PB Clear all
Completed Phase 2 Interventional Results available

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

NCT00320541
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine, paclitaxel, bevacizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
30
States / cities
Fayetteville, Arkansas • La Jolla, California • Mission Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications

NCT02604901
View directory record Official record
Conditions
Medication Adherence
Interventions
Screening and Brief Intervention (BI), Pill Box (PB)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
1,091 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Marietta, Georgia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Financial Incentives for Care Gaps

NCT03715907
View directory record Official record
Conditions
Delivery of Health Care
Interventions
Financial Incentives, Information
Behavioral
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
21 Years and older
Enrollment
8,042 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 24, 2026, 7:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

NCT07591649
View directory record Official record
Conditions
Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
Interventions
AdaptNK, Fludarabine, Cyclophosphamide, IL-2
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Recruiting No phase listed Observational

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

NCT06222164
View directory record Official record
Conditions
Hematologic Diseases
Interventions
Not listed
Lead sponsor
Invivoscribe, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Phase 2 Interventional

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

NCT00105040
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo (PB)
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
4 Years to 16 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional

Kerlix Gauze Study in a Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients

NCT00656708
View directory record Official record
Conditions
Burns, Wounds
Interventions
Kerlix AMD gauze
Other
Lead sponsor
Lucy A Wibbenmeyer
Other
Eligibility
1 Year and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 24, 2026, 7:50 AM EDT
Terminated No phase listed Observational

International Plastic Bronchitis Registry

NCT01663948
View directory record Official record
Conditions
Plastic Bronchitis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 24, 2026, 7:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

WI-INTUIT: Bridging Community Based Continence Promotion and Primary Care

NCT05664451
View directory record Official record
Conditions
Urinary Incontinence
Interventions
UI-Assist, Partnership Building
Behavioral · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
San Diego, California • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

NCT02673398
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Comprehensive Geriatric Assessment, Laboratory Biomarker Analysis, Neratinib, Pharmacological Study
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Corona, California • Duarte, California • Lancaster, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 24, 2026, 7:50 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Preference-based HIV Testing Increase Uptake in High Risk Populations?

NCT02714140
View directory record Official record
Conditions
HIV Testing
Interventions
PB-HCT ++, Economic incentive, SMS Reminder
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
1,194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Early Phase 1 Interventional

Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

NCT03568994
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Atovaquone, Cytarabine, Daunorubicin, Etoposide, Gemtuzumab Ozogamicin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 20 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

NCT02706288
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Weight loss with very low fat plant-based diet and regular exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 24, 2026, 7:50 AM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1
Drug
Lead sponsor
Orano Med Theranostics, SAS
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Building Stronger Allies

NCT03571750
View directory record Official record
Conditions
Suicide, Risk Reduction
Interventions
Building Stronger Allies, Health Education Training
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Fort Campbell North, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Phase 1 Interventional

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00004871
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
azacitidine, sodium phenylbutyrate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Oct 24, 2026, 7:50 AM EDT
Terminated Phase 1 Interventional

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

NCT03065387
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Everolimus, Neratinib, Palbociclib, Trametinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Not applicable Interventional

Multi-Method Health System Quality Improvement Intervention to Reduce Hypertension Disparities

NCT01566864
View directory record Official record
Conditions
Hypertension
Interventions
Improve clinic based measurement of blood pressure, Provider education system to promote patient-centered care, Introduce care management system in clinics
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
66,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 24, 2026, 7:50 AM EDT
Completed No phase listed Observational

A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate

NCT05421299
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 24, 2026, 7:50 AM EDT
Not listed No phase listed Observational

Samples From Leukemia Patients and Their Donors to Identify Specific Antigens

NCT02667093
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
PersImmune, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
La Jolla, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 24, 2026, 7:50 AM EDT
Completed Phase 2 Interventional

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

NCT06608901
View directory record Official record
Conditions
Sepsis-Induced Hypotension
Interventions
REGN7544, PB
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 7:50 AM EDT